Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates

Insmed (INSM) came out with a quarterly loss of $1.7 per share versus the Zacks Consensus Estimate of a loss of $1.3. This compares to a loss of $1.94 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -30.77%. A quarter ago, it was expected that this biopharmaceutical developing inhaled treatments for patients battling rare lung diseases would post a loss of $1.36 per share when it actually produced a loss of $1.42, delivering a ...